These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Nevada
|
|
45-2859440
|
|
(State or other jurisdiction of incorporation)
|
|
(I.R.S. Employer Identification No.)
|
|
Large accelerated filer ☐
|
|
Accelerated filer ☐
|
|
Non-accelerated filer ☐
|
|
Smaller reporting company ☒
|
|
|
|
|
|
(Do not check if a smaller
Reporting company)
|
|
|
|
|
|
PAGE
|
|
|
|
|
|
|
PART I - FINANCIAL INFORMATION
|
|
|
|
|
|
|
Item 1.
|
Financial Statements
|
3
|
|
|
|
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
25
|
|
|
|
|
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
32
|
|
|
|
|
|
Item 4.
|
Controls and Procedures
|
33
|
|
|
|
|
|
|
PART II - OTHER INFORMATION
|
|
|
|
|
|
|
Item 1.
|
Legal Proceedings
|
34
|
|
|
|
|
|
Item 1A.
|
Risk Factors
|
34
|
|
|
|
|
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
34
|
|
|
|
|
|
Item 3.
|
Defaults Upon Senior Securities
|
34
|
|
|
|
|
|
Item 4.
|
Mine Safety Disclosures
|
35
|
|
|
|
|
|
Item 5.
|
Other Information
|
35
|
|
|
|
|
|
Item 6.
|
Exhibits
|
36
|
|
|
|
|
|
|
SIGNATURES
|
38
|
|
|
|
PAGE
|
|
|
|
|
|
Condensed Consolidated Balance Sheets as of June 30, 2016 and December 31, 2015 (unaudited)
|
|
4
|
|
|
|
|
|
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2016 and June 30, 2015 (unaudited)
|
|
5
|
|
|
|
|
|
Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2016 and June 30, 2015 (unaudited)
|
|
6
|
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2016 and June 30, 2015 (unaudited)
|
|
7
|
|
|
|
|
|
Notes to Condensed Consolidated Financial Statements (unaudited)
|
|
8
|
|
|
June 30,
|
December 31,
|
|
|
2016
|
2015
|
|
ASSETS
|
|
|
|
Current assets
|
|
|
|
Cash
|
$
35,468
|
$
553,696
|
|
Accounts receivable, less allowance for doubtful accounts of $10,870 and $39,847 respectively
|
70,717
|
64,639
|
|
Prepaid expenses and other current assets
|
79,660
|
42,553
|
|
Total current assets
|
185,845
|
660,888
|
|
|
|
|
|
Property and equipment, at cost, less accumulated depreciation
|
18,586
|
15,108
|
|
Investments in associated companies
|
1,155
|
1,134
|
|
Intangible assets, net
|
-
|
785,070
|
|
Total assets
|
$
205,586
|
$
1,462,200
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY
|
|
|
|
Current liabilities
|
|
|
|
Accounts payable
|
$
156,640
|
$
88,774
|
|
Accrued expenses and other current liabilities
|
234,301
|
301,896
|
|
Current maturities of notes payable
|
33,591
|
32,993
|
|
Subordinated loan – related party
|
74,340
|
73,016
|
|
Total current liabilities
|
498,872
|
496,679
|
|
|
|
|
|
Notes payable, less current maturities
|
41,976
|
49,476
|
|
8% Convertible promissory notes payable, net of $1,179,181 and $722,622 discount, respectively
|
680,819
|
587,378
|
|
Total liabilities
|
1,221,667
|
1,133,533
|
|
|
|
|
|
Commitments
|
|
|
|
|
|
|
|
Stockholders' (Deficiency) Equity
|
|
|
|
|
|
|
|
Preferred stock
|
|
|
|
Authorized: $0.001 par value, 10,000,000 shares authorized
|
-
|
-
|
|
Issued and outstanding: nil preferred shares
|
|
|
|
Common stock
|
|
|
|
Authorized: $0.001 par value, 290,000,000 shares authorized
|
|
|
|
Issued and outstanding: 37,277,039 and 36,909,472, respectively
|
37,277
|
36,909
|
|
|
|
|
|
Additional paid-in capital
|
8,316,647
|
7,635,104
|
|
Accumulated other comprehensive loss
|
(295,354
)
|
(322,183
)
|
|
Accumulated deficit
|
(8,986,085
)
|
(6,994,274
)
|
|
Total Symbid Corp. stockholders' (deficiency) equity
|
(927,515
)
|
355,556
|
|
Noncontrolling interests
|
(88,566
)
|
(26,889
)
|
|
Total stockholders' (deficiency) equity
|
(1,016,081
)
|
328,667
|
|
Total liabilities and stockholders' equity
|
$
205,586
|
$
1,462,200
|
|
|
Three months ended June 30,
|
Six months ended June 30,
|
||
|
|
2016
|
2015
|
2016
|
2015
|
|
Revenues
|
|
|
|
|
|
Crowdfunding
|
$
43,549
|
$
77,804
|
$
129,642
|
$
132,198
|
|
The Funding Network
|
2,249
|
-
|
14,299
|
-
|
|
Other
|
12,158
|
14,566
|
3,309
|
34,038
|
|
Total revenues
|
57,956
|
92,370
|
147,250
|
166,236
|
|
Operating expenses
|
|
|
|
|
|
Selling, general and administrative
|
401,227
|
429,413
|
916,137
|
838,766
|
|
Professional fees
|
130,554
|
152,794
|
267,589
|
339,464
|
|
Research and development costs
|
9,540
|
26,077
|
26,658
|
48,319
|
|
Depreciation and amortization
|
37,760
|
36,202
|
74,579
|
73,140
|
|
Bad debt expense (recoveries)
|
(10,145
)
|
-
|
(29,737
)
|
-
|
|
Impairment expense
|
740,073
|
-
|
740,073
|
-
|
|
Total operating expenses
|
1,309,009
|
644,486
|
1,995,299
|
1,299,689
|
|
|
|
|
|
|
|
Operating loss
|
(1,251,053
)
|
(552,116
)
|
(1,848,049
)
|
(1,133,453
)
|
|
|
|
|
|
|
|
Other income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense and amortization of debt discount
|
(81,905
)
|
(2,566
)
|
(155,171
)
|
(5,280
)
|
|
Other income
|
484
|
-
|
455
|
11,504
|
|
Other expense
|
(2,986
)
|
(517
)
|
(2,986
)
|
(7,791
)
|
|
Total other income (expense)
|
(84,407
)
|
(3,083
)
|
(157,702
)
|
(1,567
)
|
|
|
|
|
|
|
|
Net loss
|
(1,335,460
)
|
(555,199
)
|
(2,005,751
)
|
(1,135,020
)
|
|
|
|
|
|
|
|
Net loss attributable to noncontrolling interests
|
(6,317
)
|
(18,155
)
|
(13,940
)
|
(31,003
)
|
|
|
|
|
|
|
|
Net loss attributable to Symbid Corp. stockholders
|
$
(1,329,143
)
|
$
(537,044
)
|
$
(1,991,811
)
|
$
(1,104,017
)
|
|
|
|
|
|
|
|
Basic and diluted net loss per common share
|
$
(0.04
)
|
$
(0.02
)
|
$
(0.05
)
|
$
(0.03
)
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding
|
|
|
|
|
|
Basic and diluted
|
37,119,510
|
34,705,257
|
37,014,491
|
34,394,106
|
|
|
|
|
|
|
|
Share-based compensation expense included in operating expenses:
|
|
|
|
|
|
Selling, general and administrative
|
5,239
|
$
98,147
|
$
47,578
|
$
218,437
|
|
Professional fees
|
-
|
630
|
-
|
44,842
|
|
Research and development costs
|
(2,500
)
|
16,058
|
(942
)
|
31,939
|
|
|
2,739
|
$
114,835
|
$
46,636
|
$
295,218
|
|
|
Three months ended June 30,
|
Six months ended June 30,
|
||
|
|
2016
|
2015
|
2016
|
2015
|
|
|
|
|
|
|
|
Net loss
|
$
(1,335,460
)
|
$
(555,199
)
|
$
(2,005,751
)
|
$
(1,135,020
)
|
|
Other comprehensive loss:
|
|
|
|
|
|
Foreign currency translation income (loss)
|
(5,438
)
|
14,003
|
26,829
|
(89,645
)
|
|
Comprehensive loss
|
(1,340,898
)
|
(541,196
)
|
(1,978,922
)
|
(1,224,665
)
|
|
|
|
|
|
|
|
Net loss attributable to noncontrolling interests
|
(6,317
)
|
(18,155
)
|
(13,940
)
|
(31,003
)
|
|
Foreign currency translation (loss) income attributable to noncontrolling interests
|
1,284
|
1,260
|
(1,566
)
|
10,131
|
|
Comprehensive loss attributable to
noncontrolling interests
|
(5,033
)
|
(16,895
)
|
(15,506
)
|
(20,872
)
|
|
Comprehensive loss attributable to
Symbid Corp. stockholders
|
$
(1,335,865
)
|
$
(524,301
)
|
$
(1,963,416
)
|
$
(1,203,793
)
|
|
|
Six months ended June 30,
|
|
|
|
2016
|
2015
|
|
Cash flows from operating activities
|
|
|
|
Net loss
|
$
(2,005,751
)
|
$
(1,135,020
)
|
|
Adjustments to reconcile net loss to net cash
|
|
|
|
used in operating activities
|
|
|
|
Employee and non-employee share based compensation
|
46,636
|
295,218
|
|
Depreciation and amortization
|
74,579
|
73,140
|
|
Amortization of debt discount
|
93,441
|
-
|
|
Impairment of intangible asset
|
740,073
|
-
|
|
Warrant liability - fair value adjustment
|
-
|
7,791
|
|
Provision for doubtful accounts
|
(29,737
)
|
9,945
|
|
Loss on liquidation of Symbid Italia
|
2,986
|
-
|
|
Gain on sale of investment in Gambitious B.V.
|
-
|
(11,504
)
|
|
Changes in assets and liabilities
|
|
|
|
Accounts receivable
|
24,922
|
4,963
|
|
Prepaid expenses and other current assets
|
(42,418
)
|
(14,073
)
|
|
Accounts payable
|
67,004
|
27,552
|
|
Accrued expenses and other current liabilities
|
14,673
|
(5,509
)
|
|
Net cash used in operating activities
|
(1,013,592
)
|
(747,497
)
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
Proceeds from sale of associated companies
|
$
-
|
$
20,309
|
|
Net payment from liquidation of Symbid Italia
|
(44,744
)
|
-
|
|
Acquisition of property and equipment
|
(5,784
)
|
-
|
|
Net cash (used in) provided by investing activities
|
(50,528
)
|
20,309
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
Line of credit, net
|
$
-
|
$
66,594
|
|
Repayments of notes payable
|
(8,441
)
|
(8,491
)
|
|
Proceeds from convertible notes
|
550,000
|
-
|
|
Proceeds from the issuance of common stock, net of issuance costs
|
-
|
724,116
|
|
Net cash provided by financing activities
|
541,559
|
782,219
|
|
|
|
|
|
Effect of exchange rate changes on cash
|
4,333
|
(32,130
)
|
|
Net (decrease) / increase in cash
|
(518,228
)
|
22,901
|
|
|
|
|
|
Cash and cash equivalents, beginning of period
|
553,696
|
233,068
|
|
Cash and cash equivalents, end of period
|
$
35,468
|
$
255,969
|
|
|
|
|
|
Supplemental cash flow disclosures
|
|
|
|
Interest paid
|
$
2,699
|
$
5,279
|
|
|
|
|
|
Non-cash investing and financing activities
|
|
|
|
Change in accrued expenses related to non-employee share based payments
|
$
85,274
|
$
70,351
|
|
Deconsolidatioin of Symbid Italia assets
|
5,901
|
-
|
|
Beneficial conversion feature
|
550,000
|
-
|
|
Reallocation of noncontrolling interests
|
-
|
129,918
|
|
●
|
Limited or no structured distribution channels for SME finance other than banks, increasing the mismatch between entrepreneurs and financiers;
|
|
●
|
No centralized platform for (alternative) financiers, making it difficult and inefficient to find the right financier at the right time;
|
|
●
|
No standardized data protocols for SME data, leading to costly and time-intensive (offline) screening and monitoring;
|
|
●
|
Limited financial skills of entrepreneurs leading to unnecessary inefficiencies and obstacles within the financing process; and
|
|
●
|
Decline in bank financing due to new regulations and recent financial crises, leaving a vacuum in the life cycle of SME financing.
|
|
|
June 30,
2016 |
December 31,
2015 |
|
Current assets
|
$
70,924
|
$
73,600
|
|
Current liabilities
|
$
159,492
|
$
186,214
|
|
|
June 30,
|
December 31,
|
|
|
2016
|
2015
|
|
Software
|
$
1,019,103
|
$
984,267
|
|
Less - Accumulated amortization
|
(274,394
)
|
(199,197
)
|
|
Impairment
|
(740,063
)
|
-
|
|
Translation adjustment
|
(4,646
)
|
-
|
|
|
$
-
|
$
785,070
|
|
|
June 30,
2016 |
December 31,
2015 |
|
Advisory costs
|
$
21,863
|
$
89,829
|
|
Interest
|
103,522
|
45,863
|
|
Wage tax return
|
45,264
|
19,035
|
|
Holiday pay allowance/Net salary
|
6,120
|
24,533
|
|
Penalty waiver
|
14,630
|
14,630
|
|
Marketing
|
24,568
|
38,069
|
|
Accrued stock liability
|
10,996
|
20,541
|
|
Other current liabilities
|
7,338
|
49,396
|
|
|
$
234,301
|
$
301,896
|
|
|
June 30,
|
December 31,
|
|
|
2016
|
2015
|
|
Line of credit
|
$
-
|
$
-
|
|
Working capital facility
|
75,567
|
82,469
|
|
Subordinated loan – related party
|
74,340
|
73,016
|
|
8% Convertible promissory notes, net of discount
|
680,819
|
587,378
|
|
Total notes payable
|
830,726
|
742,863
|
|
Less - Current Maturities
|
(107,931
)
|
(106,009
))
|
|
Notes payable, less current maturities
|
$
722,795
|
$
636,854
|
|
|
Principal
|
Unamortized
Debt Discount
|
Balance As of
June
30, 2016
|
|
8% Convertible promissory notes July 14, 2015
|
$
60,000
|
$
(10,654
)
|
$
49,346
|
|
8% Convertible promissory notes September 8, 2015
|
1,250,000
|
(618,527
)
|
631,473
|
|
8% Convertible promissory notes June 1, 2016
|
550,000
|
(550,000
)
|
-
|
|
|
$
1,860,000
|
$
(1,179,181
)
|
$
680,819
|
|
|
Three months ended
June 30, 2016
|
Six months ended
June 30, 2016
|
|
|
|
|
|
Cash Interest Expense
|
|
|
|
Coupon interest expense
|
$
33,396
|
$
61,730
|
|
Noncash Interest Expense
|
|
|
|
Amortization of debt discount
|
48,509
|
93,441
|
|
|
$
81,905
|
$
155,171
|
|
Year ending June 30,
|
|
|
2017
|
107,931
|
|
2018
|
33,591
|
|
2019
|
1,868,384
|
|
|
$
2,009,906
|
|
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
||
|
|
2016
|
2015
|
2016
|
2015
|
|
Symbid Coop- 100%
|
$
12,488
|
$
(5,076
)
|
$
26,205
|
$
(10,222
)
|
|
Symbid Italia – 49.9%
|
(18,805
)
|
(13,079
)
|
(40,145
)
|
(20,781
)
|
|
Total
|
$
(6,317
)
|
$
(18,155
)
|
$
(13,940
)
|
$
(31,003
)
|
|
|
June 30,
2016
|
December 31,
2015
|
|
Symbid Coop - 100%
|
$
(88,566
)
|
$
(112,614
)
|
|
Symbid Italia – 49.9%
|
-
|
85,725
|
|
Total equity (deficiency) attributable to noncontrolling interests
|
$
(88,566
)
|
$
(26,889
)
|
|
|
Three months ended June 30,
|
Six months ended June 30,
|
||
|
|
2016
|
2015
|
2016
|
2015
|
|
Revenues
|
|
|
|
|
|
Crowdfunding
|
$
43,549
|
$
77,804
|
$
129,642
|
$
132,198
|
|
The Funding Network
|
2,249
|
-
|
14,299
|
-
|
|
Other
|
12,158
|
14,566
|
3,309
|
34,038
|
|
Total revenues
|
57,956
|
92,370
|
147,250
|
166,236
|
|
Operating expenses
|
|
|
|
|
|
Selling, general and administrative
|
401,227
|
429,413
|
916,137
|
838,766
|
|
Professional fees
|
130,554
|
152,794
|
267,589
|
339,464
|
|
Research and development costs
|
9,540
|
26,077
|
26,658
|
48,319
|
|
Depreciation and amortization
|
37,760
|
36,202
|
74,579
|
73,140
|
|
Bad debt expense (recoveries)
|
(10,145
)
|
-
|
(29,737
)
|
-
|
|
Impairment expense
|
740,073
|
-
|
740,073
|
-
|
|
Total operating expenses
|
1,309,009
|
644,486
|
1,995,299
|
1,299,689
|
|
|
|
|
|
|
|
Operating loss
|
(1,251,053
)
|
(552,116
)
|
(1,848,049
)
|
(1,133,453
)
|
|
|
|
|
|
|
|
Other income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense and amortization of debt discount
|
(81,905
)
|
(2,566
)
|
(155,171
)
|
(5,280
)
|
|
Other income
|
484
|
-
|
455
|
11,504
|
|
Other expense
|
(2,986
)
|
(517
)
|
(2,986
)
|
(7,791
)
|
|
Total other income (expense)
|
(84,407
)
|
(3,083
)
|
(157,702
)
|
(1,567
)
|
|
|
|
|
|
|
|
Net loss
|
(1,335,460
)
|
(555,199
)
|
(2,005,751
)
|
(1,135,020
)
|
|
|
|
|
|
|
|
Net loss attributable to noncontrolling interests
|
(6,317
)
|
(18,155
)
|
(13,940
)
|
(31,003
)
|
|
|
|
|
|
|
|
Net loss attributable to Symbid Corp. stockholders
|
$
(1,329,143
)
|
$
(537,044
)
|
$
(1,991,811
)
|
$
(1,104,017
)
|
|
|
|
|
|
|
|
Basic and diluted net loss per common share
|
$
(0.04
)
|
$
(0.02
)
|
$
(0.05
)
|
$
(0.03
)
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding
|
|
|
|
|
|
Basic and diluted
|
37,119,510
|
34,705,257
|
37,014,491
|
34,394,106
|
|
Exhibit Number
|
|
Description of Exhibit
|
|
4.1*
|
|
Form of 2016 8% Convertible Promissory Note
|
|
|
Certification of Principal Executive Officer and Pursuant to Rule 13a-14
|
|
|
|
Certification of Principal Financial Officer Pursuant to Rule 13a-14
|
|
|
32.1
**
|
|
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
|
|
32.2
**
|
|
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
|
|
101.INS
|
|
XBRL Instance Document
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.LAB
|
|
XBRL Taxonomy Extension Labels Linkbase Document
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
SYMBID CORP.
|
|
|
|
|
|
|
August 15, 2016
|
By:
|
/s/ Korstiaan Zandvliet
|
|
|
Korstiaan Zandvliet, Chief Executive Officer
|
|
|
|
|
|
|
|
SYMBID CORP.
|
|
|
|
|
|
|
August 15, 2016
|
By:
|
/s/ Maarten van der Sanden
|
|
|
Maarten van der Sanden, Chief Financial Officer
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|